GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (ASX:CU6) » Definitions » Tax Expense

Clarity Pharmaceuticals (ASX:CU6) Tax Expense : A$0.30 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Clarity Pharmaceuticals Tax Expense?

Clarity Pharmaceuticals's tax expense for the months ended in Dec. 2023 was A$0.11 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.30 Mil.


Clarity Pharmaceuticals Tax Expense Historical Data

The historical data trend for Clarity Pharmaceuticals's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Tax Expense Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23 Jun24
Tax Expense
0.02 0.10 0.30

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Tax Expense Get a 7-Day Free Trial 0.01 0.06 0.05 0.11 0.19

Clarity Pharmaceuticals Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clarity Pharmaceuticals  (ASX:CU6) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Clarity Pharmaceuticals Tax Expense Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Clarity Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology. It operates as a single segment, which is Development of Radiopharmaceuticals. Geographically, it operates in Australia and the United States.

Clarity Pharmaceuticals Headlines

No Headlines